RE:RE:RE:RE:RE:RE:My next door neighbor and KETRUDAThe reason for the low stock price is due to UHN-REB foot dragging approval the Ph2. I thought we had support from the team at UHN. I fear big pharma may have influence with the approval processes. Here's hoping big pharma doesn't have the same influence with the FDA.
Longholder99 wrote: We need 'that' catalyst. I'd like to guess and suppose its going to be 3month data on the first round of patients that will push us into new SP territory. But I've been wrong so far in my thinking. I keep saying "this will take off when...." then it doesnt happen. Whatever is holding us up will be the last dominoe and I frankly have time to wait.....and accumulate while it drags out. So, meh....I keep working a but longer.